Juvelook Singapore: what it is, and how it differs from Sculptra
Medically reviewed by Dr Sin Yong · Last reviewed · 9 min read
Published 9 October 2026 · Reviewed by Dr Sin Yong
Juvelook is a collagen-stimulating injectable made by VAIM in Korea. Each vial combines poly-D,L-lactic acid (PDLLA) microspheres with non-cross-linked hyaluronic acid. It sits between a skin booster and a volumising filler: the hyaluronic acid gives hydration on the day, and the PDLLA prompts the skin to lay down its own collagen over the following months. Dr Sin Yong offers Juvelook at Wheelock Place, Orchard Road, and also manages excess Juvelook placed elsewhere.
Short answerJuvelook is PDLLA plus hyaluronic acid: a 50 mg vial contains 42.5 mg PDLLA and 7.5 mg hyaluronic acid, and the larger Juvelook Volume (Lenisna) 200 mg vial contains 170 mg PDLLA and 30 mg hyaluronic acid, according to the manufacturer. Its particles are smaller, rounder and more porous than Sculptra’s PLLA flakes. Hyaluronidase dissolves its hyaluronic acid but not the PDLLA. Evidence so far is from small studies.
Small case series and case reports; no randomised trial against Sculptra published
What is Juvelook?
Juvelook is an injectable collagen stimulator. The manufacturer, VAIM, classifies it as a disposable medical device and describes its intended use as the temporary improvement of facial wrinkles in adults. It is supplied as a powder that is reconstituted before injection. The active part is poly-D,L-lactic acid (PDLLA), a biodegradable polymer, in the form of microspheres; the carrier is non-cross-linked hyaluronic acid rather than the carboxymethylcellulose used in Sculptra. There are two versions: Juvelook, for skin quality and fine lines, and Juvelook Volume, sold internationally as Lenisna, with more PDLLA per vial for volume.
Juvelook, Juvelook Volume and Sculptra compared
Juvelook
Juvelook Volume / Lenisna
Sculptra
Polymer
Poly-D,L-lactic acid (PDLLA)
Poly-D,L-lactic acid (PDLLA)
Poly-L-lactic acid (PLLA)
Per vial
42.5 mg PDLLA + 7.5 mg HA
170 mg PDLLA + 30 mg HA
PLLA with carboxymethylcellulose and mannitol
Polymer structure
Amorphous
Amorphous
Semi-crystalline
Particle shape
Spherical, partly porous, ~30 µm
Spherical
Irregular sheet-like flakes, ~50 µm
Hyaluronidase
Dissolves the HA only
Dissolves the HA only
No effect
Typical use
Skin quality, fine lines, texture
Deeper volume and contour
Gradual volume through collagen
Particle data come from a 2025 laboratory comparison using electron microscopy, which found Juvelook’s particles spherical with porous structures and a mean size of about 30 µm, against Sculptra’s sheet-like particles of about 50 µm (Su, Polymers 2025). The difference in structure, amorphous PDLLA against semi-crystalline PLLA, is discussed in a 2024 review (Lee, Polymers 2024). How those physical differences translate into results in people has not been tested head to head.
Juvelook is planned for skin quality first; volume is a different decision.
Juvelook, Sculptra or a skin booster?
A skin booster such as Profhilo or a polynucleotide places hydrating or regenerative material into the skin and is not designed to build volume. Sculptra is a volumising collagen stimulator given as a course, with no product volume on the day. Juvelook sits between them: its hyaluronic acid gives some hydration immediately, and its PDLLA works on collagen over months. Juvelook Volume carries more PDLLA and is used where structure, rather than surface quality, is the aim. Which fits depends on whether the concern is the skin, the volume beneath it, or both; see collagen biostimulators and Profhilo vs Rejuran.
How Dr Sin Yong uses Juvelook
He starts by deciding whether the problem is skin quality, volume or laxity, because Juvelook answers only the first two and sagging is a lifting problem. He asks what has been injected before, since collagen stimulators and hyaluronic acid layered over several years are a common reason faces look heavy. Placement, dilution and the number of sessions are set after examination; this site does not publish session counts. He also manages the other side of the product: excess or clustered Juvelook placed elsewhere, including under the eye, for which he uses the Sculpting mode of Time Freeze Laser LCLR®, built to break up and take away the excess.
“Juvelook is a skin-quality tool first. If the real problem is sagging, more product is the wrong answer.”
Dr Sin YongOn choosing Juvelook
What the evidence shows
The published evidence is early and small. A prospective case series of 20 patients treated for nasolabial folds reported improvement on a global aesthetic scale at three months and no nodules or granulomas (Yi, J Craniofac Surg 2026). A study of PDLLA in the tear trough of Korean women reported improvement on the Hirmand classification without severe complications (Wan, J Cosmet Dermatol 2025). No randomised trial comparing Juvelook with Sculptra or with hyaluronic acid filler has been published, and much of the work comes from one research group.
Risks to know
Swelling, bruising and tenderness are expected. Nodules can occur with any collagen stimulator, and a case report described non-inflammatory nodules three weeks after PDLLA in the tear trough that resolved after treatment with an energy-based device (Seo, J Cosmet Dermatol 2025). As with any injectable, filler entering a blood vessel is the serious risk; an expert consensus on safe injection technique and the management of visual complications with the higher-concentration product was published in 2026 (Lau, J Craniofac Surg 2026). Vision change or eye pain after an injection needs emergency care immediately.
Lumps after collagen stimulators are assessed with ultrasound before anything is done.
Excess or lumpy Juvelook
Hyaluronidase dissolves Juvelook’s hyaluronic acid carrier but not the PDLLA. A firm or lumpy area is assessed with ultrasound to see where the material sits, how deep, and whether other fillers are also present. Dr Sin Yong’s approach to excess collagen-stimulator material, including under the eye, is set out on lumps after Sculptra, Radiesse, Ellansé or Juvelook.
Poly-D,L-lactic acid (PDLLA) microspheres with non-cross-linked hyaluronic acid. A 50 mg vial contains 42.5 mg PDLLA and 7.5 mg hyaluronic acid; Juvelook Volume (Lenisna) 200 mg contains 170 mg PDLLA and 30 mg hyaluronic acid, according to VAIM.
No. Both are collagen stimulators, but Juvelook uses amorphous PDLLA microspheres in hyaluronic acid, while Sculptra uses semi-crystalline PLLA particles in carboxymethylcellulose. Laboratory work found Juvelook’s particles smaller and spherical, Sculptra’s larger and sheet-like.
It sits between the two. Its hyaluronic acid gives some hydration on the day and its PDLLA works on collagen over months. Juvelook Volume carries more PDLLA and is used for structure.
Partly. Hyaluronidase dissolves the hyaluronic acid carrier but not the PDLLA. Excess Juvelook is assessed with ultrasound and managed as a collagen stimulator.
Yes, at Wheelock Place, Orchard Road, after an assessment of skin quality, volume and previous injectables. He also manages excess Juvelook placed elsewhere.
No duration can be promised. Collagen stimulators work through the body’s own collagen response, which varies between people, and published Juvelook studies have short follow-up.
References
VAIM Co., Ltd. Juvelook and Juvelook Volume (Lenisna) product information: composition and intended use. source
Su CY, et al. Physicochemical comparison of poly-D,L-lactic acid and poly-L-lactic acid injectable fillers. Polymers. 2025;18(1):84. doi:10.3390/polym18010084. source
Lee KWA, et al. Poly-D,L-lactic acid and poly-L-lactic acid fillers: a review. Polymers. 2024;16(18):2583. doi:10.3390/polym16182583. source
Yi KH, et al. Poly-D,L-lactic acid with hyaluronic acid for nasolabial folds: a prospective case series (n=20). J Craniofac Surg. 2026. doi:10.1097/SCS.0000000000012819. source
Wan J, et al. Poly-D,L-lactic acid injection for the tear trough in Korean women. J Cosmet Dermatol. 2025;24(3):e70058. doi:10.1111/jocd.70058. source
Seo SB, Wan J, Yi KH. Non-inflammatory nodules after poly-D,L-lactic acid in the tear trough treated with monopolar radiofrequency: a case report. J Cosmet Dermatol. 2025;24(1):e16575. doi:10.1111/jocd.16575. source
Lau KHE, et al. Expert consensus on safe injection technique and management of visual complications with PDLLA-HA 200. J Craniofac Surg. 2026;37(5):1103-1109. doi:10.1097/SCS.0000000000012271. source
